• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长链非编码 RNA TNRC6C-AS1 通过 Hippo 信号通路抑制 DNA 去甲基化来保护甲状腺癌中的 STK4。

Suppression of long non-coding RNA TNRC6C-AS1 protects against thyroid carcinoma through DNA demethylation of STK4 via the Hippo signalling pathway.

机构信息

Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.

Department of Thyroid and Breast Surgery, Suqian Hospital Affiliated to Xuzhou Medical University, Suqian, China.

出版信息

Cell Prolif. 2019 May;52(3):e12564. doi: 10.1111/cpr.12564. Epub 2019 Apr 1.

DOI:10.1111/cpr.12564
PMID:30938030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6536409/
Abstract

OBJECTIVES

Thyroid carcinoma (TC) represents a malignant neoplasm affecting the thyroid. Current treatment strategies include the removal of part of the thyroid; however, this approach is associated with a significant risk of developing hypothyroidism. In order to adequately understand the expression profiles of TNRC6C-AS1 and STK4 and their potential functions in TC, an investigation into their involvement with Hippo signalling pathway and the mechanism by which they influence TC apoptosis and autophagy were conducted.

METHODS

A microarray analysis was performed to screen differentially expressed lncRNAs associated with TC. TC cells were employed to evaluate the role of TNRC6C-AS1 by over-expression or silencing means. The interaction of TNRC6C-AS1 with methylation of STK4 promoter was evaluated to elucidate its ability to elicit autophagy, proliferation and apoptosis.

RESULTS

TNRC6C-AS1 was up-regulated while STK4 was down-regulated, where methylation level was elevated. STK4 was verified as a target gene of TNRC6C-AS1, which was enriched by methyltransferase. Methyltransferase's binding to STK4 increased expression of its promoter. Over-expressed TNRC6C-AS1 inhibited STK4 by promoting STK4 methylation and reducing the total protein levels of MST1 and LATS1/2. The phosphorylation of YAP1 phosphorylation was decreased, which resulted in the promotion of SW579 cell proliferation and tumorigenicity.

CONCLUSION

Based on our observations, we subsequently confirmed the anti-proliferative, pro-apoptotic and pro-autophagy capabilities of TNRC6C-AS1 through STK4 methylation via the Hippo signalling pathway in TC.

摘要

目的

甲状腺癌(TC)是一种影响甲状腺的恶性肿瘤。目前的治疗策略包括切除部分甲状腺;然而,这种方法与发生甲状腺功能减退的风险显著相关。为了充分了解 TNRC6C-AS1 和 STK4 的表达谱及其在 TC 中的潜在功能,研究了它们与 Hippo 信号通路的关系,以及它们影响 TC 细胞凋亡和自噬的机制。

方法

进行了微阵列分析,以筛选与 TC 相关的差异表达 lncRNA。使用 TC 细胞通过过表达或沉默手段来评估 TNRC6C-AS1 的作用。评估了 TNRC6C-AS1 与 STK4 启动子甲基化的相互作用,以阐明其诱导自噬、增殖和凋亡的能力。

结果

TNRC6C-AS1 上调,而 STK4 下调,甲基化水平升高。验证 STK4 是 TNRC6C-AS1 的靶基因,被甲基转移酶富集。甲基转移酶与 STK4 的结合增加了其启动子的表达。过表达的 TNRC6C-AS1 通过促进 STK4 甲基化和降低 MST1 和 LATS1/2 的总蛋白水平来抑制 STK4。YAP1 磷酸化减少,促进 SW579 细胞增殖和致瘤性。

结论

基于我们的观察结果,我们随后通过 Hippo 信号通路证实了 TNRC6C-AS1 通过 STK4 甲基化在 TC 中具有抗增殖、促凋亡和促自噬的能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/2aba9e786075/CPR-52-e12564-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/b8897f192951/CPR-52-e12564-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/cef2ebb90d6f/CPR-52-e12564-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/5df713ccc9fe/CPR-52-e12564-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/f7d1b8397ea1/CPR-52-e12564-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/33f998207617/CPR-52-e12564-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/b6e9ef23cee4/CPR-52-e12564-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/2aba9e786075/CPR-52-e12564-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/b8897f192951/CPR-52-e12564-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/cef2ebb90d6f/CPR-52-e12564-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/5df713ccc9fe/CPR-52-e12564-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/f7d1b8397ea1/CPR-52-e12564-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/33f998207617/CPR-52-e12564-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/b6e9ef23cee4/CPR-52-e12564-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e62e/6536409/2aba9e786075/CPR-52-e12564-g007.jpg

相似文献

1
Suppression of long non-coding RNA TNRC6C-AS1 protects against thyroid carcinoma through DNA demethylation of STK4 via the Hippo signalling pathway.长链非编码 RNA TNRC6C-AS1 通过 Hippo 信号通路抑制 DNA 去甲基化来保护甲状腺癌中的 STK4。
Cell Prolif. 2019 May;52(3):e12564. doi: 10.1111/cpr.12564. Epub 2019 Apr 1.
2
Long non-coding RNA TNRC6C-AS1 promotes methylation of STK4 to inhibit thyroid carcinoma cell apoptosis and autophagy via Hippo signalling pathway.长链非编码 RNA TNRC6C-AS1 通过 Hippo 信号通路促进 STK4 的甲基化,从而抑制甲状腺癌细胞凋亡和自噬。
J Cell Mol Med. 2020 Jan;24(1):304-316. doi: 10.1111/jcmm.14728. Epub 2019 Oct 27.
3
LncRNA TNRC6C-AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR-129-5p.长链非编码 RNA TNRC6C-AS1 通过作为 miR-129-5p 的竞争性内源 RNA 调控甲状腺癌细胞中的 UNC5B 影响细胞增殖、迁移和侵袭。
J Cell Biochem. 2018 Nov;119(10):8304-8316. doi: 10.1002/jcb.26868. Epub 2018 Jun 12.
4
Long non-coding RNA PRRT3-AS1 silencing inhibits prostate cancer cell proliferation and promotes apoptosis and autophagy.长链非编码 RNA PRRT3-AS1 沉默抑制前列腺癌细胞增殖并促进细胞凋亡和自噬。
Exp Physiol. 2020 May;105(5):793-808. doi: 10.1113/EP088011. Epub 2020 Apr 22.
5
Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis.长链非编码 RNA NR2F1-AS1 通过调控 miRNA-338-3p/CCND1 轴促进甲状腺癌细胞的增殖、迁移,抑制其凋亡。
J Cell Mol Med. 2019 Sep;23(9):5907-5919. doi: 10.1111/jcmm.14386. Epub 2019 Jul 14.
6
Knockdown of lncRNA LEF1-AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway.长链非编码 RNA LEF1-AS1 的敲低通过 Hippo 信号通路抑制口腔鳞状细胞癌 (OSCC) 的进展。
Cancer Biol Ther. 2019;20(9):1213-1222. doi: 10.1080/15384047.2019.1599671. Epub 2019 Apr 14.
7
Silencing long non-coding RNA DLX6-AS1 or restoring microRNA-193b-3p enhances thyroid carcinoma cell autophagy and apoptosis via depressing HOXA1.沉默长链非编码 RNA DLX6-AS1 或恢复 microRNA-193b-3p 通过抑制 HOXA1 增强甲状腺癌细胞自噬和凋亡。
J Cell Mol Med. 2021 Oct;25(19):9319-9330. doi: 10.1111/jcmm.16868. Epub 2021 Sep 12.
8
LncRNA STK4 antisense RNA 1 (STK4-AS1) promoted osteosarcoma by inhibiting p53 expression.长链非编码RNA STK4反义RNA 1(STK4-AS1)通过抑制p53表达促进骨肉瘤发生。
Cancer Biomark. 2023;36(1):1-16. doi: 10.3233/CBM-210291.
9
Long non-coding RNA LINC00607 silencing exerts antioncogenic effects on thyroid cancer through the CASP9 Promoter methylation.长链非编码RNA LINC00607沉默通过半胱天冬酶9(CASP9)启动子甲基化对甲状腺癌发挥抗癌作用。
J Cell Mol Med. 2021 Aug;25(16):7608-7620. doi: 10.1111/jcmm.16265. Epub 2021 Jul 7.
10
Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway.下调长非编码 RNA RNAZFHX4-AS1 通过 FAT4 依赖性 Hippo 信号通路抑制乳腺癌细胞的侵袭和迁移。
Cancer Gene Ther. 2019 Nov;26(11-12):374-387. doi: 10.1038/s41417-018-0066-6. Epub 2018 Dec 14.

引用本文的文献

1
Integrative analysis of exosomal ncRNAs and their regulatory networks in liver cancer progression.外泌体非编码RNA及其调控网络在肝癌进展中的综合分析
Pract Lab Med. 2025 Mar 21;45:e00464. doi: 10.1016/j.plabm.2025.e00464. eCollection 2025 Jul.
2
SIRT7 affects the proliferation and apoptosis of papillary thyroid cancer cells by desuccinylation of LATS1.SIRT7通过使LATS1去琥珀酰化来影响甲状腺乳头状癌细胞的增殖和凋亡。
BMC Cancer. 2025 Mar 6;25(1):408. doi: 10.1186/s12885-025-13779-9.
3
Interaction of noncoding RNAs with hippo signaling pathway in cancer cells and cancer stem cells.

本文引用的文献

1
Mapping the STK4/Hippo signaling network in prostate cancer cell.绘制前列腺癌细胞中的STK4/河马信号网络。
PLoS One. 2017 Sep 7;12(9):e0184590. doi: 10.1371/journal.pone.0184590. eCollection 2017.
2
A potential role for the Hippo pathway protein, YAP, in controlling proliferation, cell cycle progression, and autophagy in BCPAP and KI thyroid papillary carcinoma cells.河马通路蛋白YAP在控制BCPAP和KI甲状腺乳头状癌细胞的增殖、细胞周期进程及自噬方面的潜在作用。
Am J Transl Res. 2017 Jul 15;9(7):3212-3223. eCollection 2017.
3
Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
非编码RNA与癌细胞和癌症干细胞中河马信号通路的相互作用。
Noncoding RNA Res. 2024 Jun 6;9(4):1292-1307. doi: 10.1016/j.ncrna.2024.06.006. eCollection 2024 Dec.
4
Dysregulated Expression Patterns of Circular RNAs in Cancer: Uncovering Molecular Mechanisms and Biomarker Potential.癌症中环状RNA的表达模式失调:揭示分子机制和生物标志物潜力
Biomolecules. 2024 Mar 22;14(4):384. doi: 10.3390/biom14040384.
5
Elucidating hepatocellular carcinoma progression: a novel prognostic miRNA-mRNA network and signature analysis.阐明肝细胞癌的进展:一种新的预后 miRNA-mRNA 网络和特征分析。
Sci Rep. 2024 Feb 29;14(1):5042. doi: 10.1038/s41598-024-55806-y.
6
The emerging roles of N6-methyladenosine RNA modifications in thyroid cancer.N6-甲基腺苷 RNA 修饰在甲状腺癌中的新兴作用。
Eur J Med Res. 2023 Nov 1;28(1):475. doi: 10.1186/s40001-023-01382-2.
7
Targeting Hippo signaling in cancer: novel perspectives and therapeutic potential.靶向癌症中的Hippo信号通路:新观点与治疗潜力
MedComm (2020). 2023 Oct 3;4(5):e375. doi: 10.1002/mco2.375. eCollection 2023 Oct.
8
New biomarkers: prospect for diagnosis and monitoring of thyroid disease.新生物标志物:甲状腺疾病的诊断和监测前景。
Front Endocrinol (Lausanne). 2023 Jul 21;14:1218320. doi: 10.3389/fendo.2023.1218320. eCollection 2023.
9
The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy.河马激酶MST1/2在心血管和代谢疾病中的作用:药物治疗中一个有前景的治疗靶点选择
Acta Pharm Sin B. 2023 May;13(5):1956-1975. doi: 10.1016/j.apsb.2023.01.015. Epub 2023 Feb 3.
10
A novel autophagy-related long non-coding RNAs signature predicting progression-free interval and I-131 therapy benefits in papillary thyroid carcinoma.一种预测甲状腺乳头状癌无进展生存期和I-131治疗获益的新型自噬相关长链非编码RNA特征。
Open Med (Wars). 2023 Mar 3;18(1):20230660. doi: 10.1515/med-2023-0660. eCollection 2023.
全基因组表达筛选揭示参与甲状腺癌发生的长链非编码RNA
J Clin Endocrinol Metab. 2016 Nov;101(11):4005-4013. doi: 10.1210/jc.2016-1991. Epub 2016 Jul 26.
4
The role of photobiomodulation on gene expression of cell adhesion molecules in diabetic wounded fibroblasts in vitro.光生物调节对体外培养的糖尿病伤口成纤维细胞中细胞粘附分子基因表达的作用。
J Photochem Photobiol B. 2016 Aug;161:368-74. doi: 10.1016/j.jphotobiol.2016.05.027. Epub 2016 Jun 1.
5
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
6
Cancer statistics, 2016.癌症统计数据,2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
7
Thyroid carcinoma in Graves' disease: A meta-analysis.格雷夫斯病中的甲状腺癌:一项荟萃分析。
Int J Surg. 2016 Mar;27:118-125. doi: 10.1016/j.ijsu.2015.11.027. Epub 2015 Nov 26.
8
STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.STK4调节Toll样受体(TLR)信号通路,并预防慢性炎症相关的肝细胞癌。
J Clin Invest. 2015 Nov 2;125(11):4239-54. doi: 10.1172/JCI81203. Epub 2015 Oct 12.
9
Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR).长链非编码RNA PVT1通过招募EZH2并调节促甲状腺激素受体(TSHR)来调控甲状腺癌细胞的增殖。
Tumour Biol. 2016 Mar;37(3):3105-13. doi: 10.1007/s13277-015-4149-9. Epub 2015 Oct 1.
10
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.NF2缺失通过YAP依赖的RAS蛋白反式激活促进致癌RAS诱导的甲状腺癌,并使其对MEK抑制敏感。
Cancer Discov. 2015 Nov;5(11):1178-93. doi: 10.1158/2159-8290.CD-15-0330. Epub 2015 Sep 10.